Defined origin and composition
Derived from B. breve BB091109 and produced as a non-viable preparation with characterised components.
FLAGSHIP POSTBIOTIC INGREDIENT
Meet VMK223. A postbiotic developed around host biology.
VMK223 is veMico’s proprietary non-viable postbiotic derived from Bifidobacterium breve BB091109. Developed through targeted microbial research, it combines a characterised preparation with laboratory host-response investigations, two published standalone human studies and practical formulation experience.
THE INGREDIENT
Defined origin. Characterised composition.
VMK223 is a proprietary preparation containing exopolysaccharide and microbial cell-wall components. Its composition and production process form the basis for ingredient identity, quality assessment and technical evaluation.
Host-response research
Mechanistic investigations have examined TLR2- and TLR4-associated signalling and related host-response pathways. These laboratory findings do not establish the mechanism behind human trial outcomes.
Published human evidence
Two published randomised, placebo-controlled standalone studies investigated VMK223 at 500 mg/day over 12 weeks in women aged 40–55.
Read the published studies →STANDALONE HUMAN RESEARCH
Published clinical evidence across women's health and skin health.
VMK223 has been evaluated in randomised, placebo-controlled human studies investigating inflammatory and hormonal biomarkers and skin health outcomes. Two standalone studies have been published in peer-reviewed journals. Additional human investigations, including dose-response research, further support the development of VMK223.
STANDALONE VMK223 · 500 MG/DAY · 12 WEEKS
Women's Health — Motei et al., 2023
A 12-week randomised, placebo-controlled study in women demonstrated significant reductions in inflammatory markers, including CRP (5.09 to 3.14 mg/L) and IL-6 (3.92 to 2.81 pg/mL) in the VMK223 group, alongside favourable changes in selected hormonal biomarkers.
Explore the study →STANDALONE VMK223 · 500 MG/DAY · 12 WEEKS
Skin Health — Pipino et al., 2026
A 12-week randomised, placebo-controlled study demonstrated a 28% reduction in wrinkle depth, 28% improvement in skin hydration and 27% improvement in elasticity from baseline.
Explore the study →FORMULATION RELEVANCE
Formulation possibilities without the viability requirement.
As a non-viable preparation, VMK223 does not require maintenance of live microbial viability. It can be evaluated for capsules, powders, sachets and other suitable delivery formats. Available stability data, processing conditions and compatibility need review for each proposed formulation.
Explore applications →
COMMERCIAL APPLICATIONS
Technology already used in finished products.
Y SKIN capsules and Y GUT sensitive powder illustrate veMico’s ingredient incorporation experience. Research on these finished products is distinct from controlled trials of standalone VMK223.
Y SKIN · Beauty from within
A finished capsule product providing 500 mg VMK223 per daily serving in the beauty-from-within category.
Explore the consumer study →
Y GUT sensitive · Gut-oriented powder
A powder formulation combining 200 mg VMK223 with prebiotic galactooligosaccharides (GOS).
Explore the consumer study →PARTNER EVALUATION
Bring VMK223 into your next product.
Speak to the veMico team about ingredient documentation, scientific evidence, formulation requirements and commercial supply.
Request Technical Information →